KIT and cancer: In the present study, we evaluated SCF as an effective vector to target mutant-KIT-driven GIST cancer cells, and the conjugated drug SCF-DM1 was tested for its efficacy in mutant-KIT-driven GIST cells in vitro and in vivo with a xenograft mouse model.